Impact of HbA1c criterion on the definition of glycemic component of the metabolic syndrome: the China health and nutrition survey 2009 by Xingxing Sun et al.
Sun et al. BMC Public Health 2013, 13:1045
http://www.biomedcentral.com/1471-2458/13/1045RESEARCH ARTICLE Open AccessImpact of HbA1c criterion on the definition of
glycemic component of the metabolic syndrome:
the China health and nutrition survey 2009
Xingxing Sun1†, Tingting Du2†, Rui Huo2, Xuefeng Yu2* and Lixian Xu1*Abstract
Background: In 2009, a unified definition of metabolic syndrome (MetS) was proposed, of which, the glycemic
component is defined on the basis of fasting plasma glucose (FPG) level. Recently, the American Diabetes
Association (ADA) recommended the use of glycated hemoglobin (HbA1c) as an alternative to FPG to define
prediabetes. Hence, we aim to compare the performance of HbA1c and FPG in the definition of glycemic
component of the MetS among Chinese adults.
Methods: We conducted a cross-sectional analysis of 7641 Chinese participants aged ≥18 years using data from
the China Health and Nutrition Survey 2009. MetS was defined according to the consensus criteria in 2009. We
compared the use of HbA1c versus FPG in the definition of the glycemic component of MetS. Increased HbA1c
value was defined following the criterion of HbA1c cut-off point of ≥5.7% recommended by the ADA.
Results: Overall, 1136 (14.9%) had MetS according to FPG ≥ 5.6 mmol/l, and 1640 (21.5%) had MetS according to
HbA1c ≥ 5.7%. Compared with individuals with FPG-based diagnosis of MetS, individuals with HbA1c-based
diagnosis of MetS were older, had higher levels of LDL-C, magnesium, and transferrin, and lower levels of uric acid.
Of those found to have MetS according to either FPG or HbA1c (n = 2008), overlap between HbA1c- and FPG-
based diagnosis of MetS was limited (n = 768, 38.2%). The overlap index regarding MetS diagnosed by FPG or
HbA1c persisted low in each evaluated subgroup (≤ 50.0%).
Conclusions: We note limited overlap and poor agreement between FPG- and HbA1c-based diagnosis of MetS. Screening
MetS through introduction of HbA1c in addition to FPG could contribute to identification of more people with MetS.
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The metabolic syndrome (MetS), characterized by abdom-
inal obesity, hypertriglyceridemia, low high-density lipo-
protein cholesterol (HDL-C) level, high blood pressure
(BP), and increased fasting glucose level, predisposes indi-
viduals to a high risk for cardiovascular disease (CVD) and
diabetes [1-4]. The MetS is a common disorder in China.
According to data from the International Collaborative
Study of Cardiovascular Disease in ASIA, 64 (15.1%) mil-
lion adults aged 35–74 years have the MetS according to* Correspondence: xfyu188@163.com; lixianxu1237@163.com
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reproduction in any medium, provided the orthe modified Adult Treatment Panel III (ATP III) criteria
[5]. The ATP III criteria were slightly modified by lower-
ing the threshold for fasting plasma glucose (FPG) to
5.6 mmol/l in 2004 by the American Heart Association/
National Heart, Lung, and Blood Institute (AHA/NHLBI)
[6,7] to be consistent with the American Diabetes Associ-
ation (ADA) criteria for impaired fasting glucose (IFG) [8].
Most recently, several major organizations, led by the
International Diabetes Federation (IDF) and AHA/NHLBI,
proposed a unified definition of MetS in 2009 [9], while
the ADA recommended the use of glycated hemoglobin
(HbA1c) as an alternative to IFG to define the category of
increased diabetes risk in 2010 [10]. Studies from the USA
and Europe showed that HbA1c can be used instead of. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dence has suggested that HbA1c value might differ ac-
cording to ethnic origin [11]. Whether HbA1c can be used
instead of FPG in the definition of MetS in Chinese popu-
lation remains unknown. Hence, we took advantage of the
large representative sample of Chinese adults who partici-
pated in the China Health and Nutrition Survey (CHNS)
2009 to compare the uses of HbA1c ≥ 5.7% or FPG
≥ 5.6 mmol/l in the definition of the glycemic component
of MetS. In addition, as prior evidence provided mixed re-
sults as to whether the presence of MetS aggravates
cardiovascular risk in diabetic patients [12-14], we re-
peated the analysis in participants without diabetes (FPG
≥7.0 mmol/l or HbA1c ≥6.5%).
Methods
Study design
The CHNS, which included a sample representative 56%
of the Chinese population, is the only large-scale longi-
tudinal, national survey in China. It was designed to ex-
plore how the social and economic transformation of
Chinese society is affecting the health and nutritional
status of the Chinese population. The CHNS rounds
were conducted in 1989, 1991, 1993, 1997, 2000, 2004,
2006, 2009 and 2011. For each round, a stratified multi-
stage, random cluster process was used to draw study
sample from nine provinces (Liaoning, Heilongjiang,
Jiangsu, Shandong, Henan, Hubei, Hunan, Guangxi and
Guizhou) that vary significantly in terms of geography,
economic development, and health status. Counties in
the nine provinces were stratified by income (low, mid-
dle and high) and a weighted sampling scheme was used
to select randomly four counties in each province. At
last, the CHNS collected health data in 228 commu-
nities. Full details of the CHNS have been described
elsewhere [15]. Each participant provided a written in-
formed consent and the study was approved by the insti-
tutional review committees of the University of North
Carolina at Chapel Hill, the National Institute of Nutri-
tion and Food Safety, Chinese Center for Disease Con-
trol and Prevention, and the China-Japan Friendship
Hospital, Ministry of Health.
Study population
Since fasting blood samples were initially collected in
2009, this study examined data from the CHNS 2009.
The 2009 examination surveyed 10039 participants
aged ≥ 18 years. All participants were asked to complete
a structured questionnaire which provided information
on age, sex, urban/rural settings, educational attainment,
histories of current and previous illness, and medical
treatment and so on. Participants were included in the
present analysis if they were 18 years or older. Exclusion
criteria included pregnancy, a self-reported diabetesdiagnosis or diabetes medication use, no information on
age, body mass index (BMI), HbA1c, or five components
of MetS, and anemia (hemoglobin <13 g/dl in men,
and <12 g/dl in women). The remaining available 7641
participants with anthropometry and clinical examin-
ation information were included in our analysis.Anthropometry measurements
Weight, height, waist circumference (WC) and BP were
measured following standardized protocols from the World
Health Organization (WHO). Weight was measured with
the participants wearing light clothing on a calibrated beam
balance and height was measured without shoes using
a portable SECA stadiometer (Seca North America East,
Hanover, MD, USA). Body mass index (BMI) was calcu-
lated as weight (in kilograms) divided by the square of
height (in meters). WC was measured with an inelastic tape
to the nearest 0.1 cm at a midpoint between the bottom of
the rib cage and the top of the iliac crest at the end of ex-
halation. BP was measured by trained examiners using a
mercury sphygmomanometer with appropriate cuff at
three different consecutive times at 3–5 min intervals on
one visit. The three readings were averaged as the BP
values in our data analysis. All physical examinations were
performed at the same location and followed the same
protocol.Biochemical measurements
Blood was collected after an overnight fast by venipuncture.
Samples for FPG and HbA1c measurements were centri-
fuged and tested immediately. Serum samples for determi-
nations of CVD risk factors, except for FPG and HbA1c,
were then frozen, and stored at −86°C for later laboratory
analysis. All blood samples were analyzed in a national
central lab in Beijing (medical laboratory accreditation cer-
tificate ISO15189:2007). Glucose was measured with a
Hitachi 7600 analyzer by GOD-PAP method [Randox La-
boratories Ltd, UK]. HbA1c was measured with high per-
formance liquid chromatography (HPLC) system [model
HLC-723 G7; Tosoh Corporation, Tokyo, Japan]. Lipids
(total cholesterol [TC], triglycerides [TG], low density
lipoprotein cholesterol [LDL-C], and HDL-C), serum albu-
min, uric acid, alanine aminotransferase, magnesium, and
hypersensitive-C reactive protein (hs-CRP) were measured
using a biochemical autoanalyzer (Hitachi 7600 auto-
mated analyzer, Tokyo, Japan). Hs-CRP was determined by
the immunoturbidimetric method. Fasting insulin concen-
tration was measured using the radioimmunology assay
(Gamma counter XH-6020, China). Homeostasis model
assessment of insulin resistance (HOMA2-IR) was calcu-
lated using the HOMA2 calculator updated in 2007 be-
cause it is more accurate than the original HOMA1
method (based on explicit formulas) [16].
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The MetS was defined according to the consensus criteria
in 2009 [9]. Persons with MetS are those with the presence
of three or more of the following criteria: elevated WC, de-
fined using population- and country-specific cut points
(for Chinese, the cut points for WC were ≥ 85 cm in
men and ≥ 80 cm in women); TG ≥ 1.7 mmol/l; HDL-C
<1.0 mmol/l in men and < 1.3 mmol/l in women; BP
≥ 130/85 mmHg or on antihypertensive drug treatment
in a patient with a history of hypertension; or FPG
≥ 5.6 mmol/l. According to 2010 ADA criteria [10], dys-
glycemia is defined as FPG ≥ 5.6 mmol/l or HbA1c ≥ 5.7%.
Statistical analysis
All statistical analyses were performed using SPSS soft-
ware (version 12.0 for windows; SPSS, Chicago, IL,
USA). Continuous variables were presented as mean ±
SD or medians (25th to 75th percentiles) as appropriate.
Categorical variables were presented as numbers and
percentages. One-way ANOVA was applied to compare
differences in means across groups. Kruskal-Wallis ana-
lysis of median test was used followed by the Mann–
Whitney U test for pairwise comparisons. Chi-square
test was performed to assess differences in proportions
across groups. Bonferroni correction was applied to ad-
just P-values for multiple comparisons. Analysis were
stratified by sex, age groups (18–44 years, 45–64 years,
and ≥ 65 years), urban/rural settings, regions (Southern
[Jiangsu, Hubei, Hunan, Guangxi, Guizhou]/Northern
[Liaoning, Heilongjiang, Shandong, Henan]), educational
attainments (Primary or below, less than high school,
high school or above), BMI categories, WC groups,
and BP status. The uses of HbA1c ≥ 5.7% or FPG
≥ 5.6 mmol/l in the definition of the glycemic component
of MetS were compared. The kappa (ҝ) statistic was
calculated to test for an agreement between FPG- and
HbA1c-based identification of MetS. Venn diagram was
constructed as a visual display of concordance/discord-
ance between FPG- and HbA1c-based identification of
MetS. The diagnostic property of HbA1c ≥ 5.7% in identi-
fying MetS was evaluated by receiver operating character-
istic (ROC) curve. A two-tailed P value of < 0.05 was
considered to be significant.
Results
Prevalence of metabolic syndrome
Of the 7641 persons without a history of diabetes, 1136
(14.9%) met MetS using the FPG criterion, and 1640
(21.5%) met MetS using the HbA1c criterion. The pro-
portion of FPG-based diagnosis of MetS remained stable
between genders (15.0% in men and 14.8% in women,
P = 0.63), while women had a significantly higher pro-
portion of HbA1c-based diagnosis of MetS than men
(19.7% in men and 23.0% in women, P < 0.001). Theprevalence of FPG- and HbA1c-based diagnosis of MetS
increased with age (Table 1). However, the age-related
gradient was notably steeper for HbA1c-based definition
of MetS than FPG-based definition of MetS. For each
age group, the prevalence of HbA1c-based identification
of MetS was significantly higher than that of FPG-based
definition of MetS. Similar significant trends were noted
in urban/rural settings, regions, all education groups,
BMI and WC categories, and all BP status.
Overlap between FPG- and HbA1c-based definition of
metabolic syndrome
Of those found to have MetS by either FPG or HbA1c
(n = 2008, 26.3%), overlap between HbA1c- and FPG-
based diagnosis of MetS was limited (n = 768, 38.2%)
(Figure 1). The ҝ coefficient of the FPG criterion with
HbA1c criterion for the diagnosis of MetS was 0.458.
Using FPG-based diagnosis of MetS as the reference
standard, the HbA1c cut-point of 5.7% in identifying sub-
jects with MetS demonstrated a sensitivity of 60.3%, spe-
cificity of 76.2%, positive predictive value of 30.6%, and
negative predictive value of 91.7%. ROC curve analysis
with HbA1c as a continuous variable yielded an area under
the curve of 0.74 (P < 0.01). The overlap index regarding
MetS diagnosed by FPG and HbA1c was low irrespective
of sex, age, urban/rural setting, region, educational attain-
ment, BMI, WC and BP status (Table 2). The magnitude
of overlap between the two criteria slightly increased with
increasing age, worsening BMI, WC, and BP.
Similar to the overall cohort, in the non-diabetes
group, overlap between HbA1c- and FPG-based diagno-
sis of MetS was even more limited (5.9%). The ҝ coeffi-
cient of the FPG criterion with HbA1c criterion for the
diagnosis of MetS was 0.322.
Characteristics of individuals diagnosed with metabolic
syndrome by each measure
As expected, the worst CVD risk profile was found in in-
dividuals with MetS based upon both FPG and HbA1c
and the most favorable cardiovascular profile was found
in individuals without MetS (Table 3). The characteris-
tics differed for individuals with FPG-based diagnosis of
MetS compared with participants with HbA1c-based
diagnosis of MetS. Specifically, participants with HbA1c-
based diagnosis of MetS were older, had higher levels of
HbA1c, LDL-C, magnesium, and transferrin, and lower
levels of FPG, and uric acid. Results were largely repli-
cated when the same analysis were conducted in the
non-diabetes group (Additional file 1).
Discussion
In the present study, we compared HbA1c and FPG in
the definition of glycemic component of MetS. We saw
low magnitude of overlap and poor agreement between
Table 1 Prevalence of metabolic syndrome (MetS) according to fasting plasma glucose or HbA1c or both




MetS by both FPG and
HbA1c
ҝ coefficient*
ALL 5633 (73.7) 368 (4.8) 872 (11.4) 768 (10.1) 0.458
Sex
Men 2731 (75.3) 179 (5.0) 353 (9.7) 361 (10.0) 0.489
Women 2902 (72.3) 189 (4.7) 519 (12.9) 407 (10.1) 0.432
Age, y
18-44 2434 (86.6) 88 (3.1) 176 (6.3) 113 (4.0) 0.412
45-64 2407 (68.4) 214 (6.1) 475 (13.5) 423 (12.0) 0.431
≥ 65 792 (60.5) 66 (5.0) 221 (16.8) 232 (17.7) 0.474
BMI categories
< 25 kg/m2 4462 (83.1) 189 (3.5) 409 (7.6) 310 (5.8) 0.449
25-30 kg/m2 1056 (53.9) 148 (7.6) 395 (20.2) 359 (18.3) 0.376
≥ 30 kg/m2 115 (36.8) 31 (9.9) 68 (21.7) 99 (31.6) 0.375
WC categories
< 85/80 cm 3507 (93.6) 44 (1.2) 119 (3.2) 72 (2.0) 0.448
≥ 85/80 cm 2126 (54.5) 324 (8.3) 753 (19.3) 696 (17.9) 0.371
BP status
< 120/80 mmHg 2159 (91.5) 46 (2.0) 101 (4.3) 53 (2.2) 0.388
120/80-140/
90 mmHg
2532 (75.9) 150 (4.5) 346 (10.4) 307 (9.2) 0.467
≥140/90 mmHg 942 (48.4) 172 (8.8) 425 (21.8) 408 (21.0) 0.349
Settings
Urban 1785 (72.8) 146 (5.9) 287 (11.7) 236 (9.6) 0.412
Rural 3848 (74.2) 222 (4.3) 585 (11.3) 532 (10.2) 0.478
Regions
Southern 3438 (78.9) 224 (5.1) 392 (9.0) 304 (7.0) 0.416
Northern 2195 (66.9) 144 (4.4) 480 (14.6) 464 (14.1) 0.481
Education
Primary or below 2367 (69.5) 171 (5.0) 471 (13.8) 396 (11.7) 0.439
Less than high
school
1900 (76.9) 121 (4.9) 232 (9.3) 220 (8.9) 0.472
High school or
above
1366 (77.5) 76 (4.3) 169 (9.6) 152 (8.6) 0.474
Data are numbers (percentages).
*An agreement between FPG- and HbA1c- based identification of MetS.
FPG, fasting plasma glucose; BMI, body mass index; WC, waist circumference; BP, blood pressure.
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significant trends were noted in each evaluated sub-
group. The prevalence of HbA1c-based diagnosis of
MetS was significantly higher than FPG-based diagnosis
of MetS. Screening MetS by introduction of the new
HbA1c criterion in addition to assessment of the FPG
could contribute to identification of more people with
MetS.
Our results are in line with the study from an European
country with respect to a higher prevalence of MetS mea-
sured by HbA1c than by FPG [17]. Evidence has suggestedthat there were a large proportion of Chinese with isolated
postprandial hyperglycemia [18]. Although postprandial
glucose were not available in the present study, it is pos-
sible that even with normal fasting glucose, individuals
may have postprandial hyperglycemia. HbA1c represents
chronic exposure to basal and postprandial hyperglycemia.
Hence, HbA1c can identify more individuals with MetS
than FPG.
In the present CHNS cohort, HbA1c-based diagnosis of
MetS illustrated limited overlap with FPG-based diagnosis
of MetS. This deviates from the findings of the cohort
Figure 1 Venn diagram for individuals meeting FPG- and
HbA1c-based diagnosis of metabolic syndrome: the
CHNS 2009.
Table 2 Proportions of metabolic syndrome (MetS) by fasting





Men 893 179 (20.0)
Women 1115 189 (17.0)
Age, y
18-44 377 88 (23.3)
45-64 1112 214 (19.2)
≥ 65 519 66 (12.7)
BMI categories
< 25 kg/m2 908 189 (20.8)
25-30 kg/m2 902 148 (16.4)
≥ 30 kg/m2 198 31 (15.7)
WC categories
< 85/80 cm 235 44 (18.7)
≥ 85/80 cm 1773 324 (18.3)
BP status




≥140/90 mmHg 1005 172 (17.1)
Settings
Urban 669 146 (21.8)
Rural 1339 222 (16.6)
Regions
Southern 920 224 (24.3)
Northern 1088 144 (13.2)
Education







*Proportions of overlap between HbA1c- and FPG-based diagnosis of MetS are calc
of MetS based on either FPG or HbA1c.
FPG, fasting plasma glucose; BMI, body mass index; WC, waist circumference; BP, bl
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which a good agreement between HbA1c- and FPG-based
identification of MetS was observed [17,19]. Hence, a dis-
crepancy in the degree of overlap might be more likely to
happen in Chinese than in US and European adults. The
inconsistency between the cited studies and our present
study may be attributed to the discrepancies in ethnicity,
socio-demographic or personal characteristics, preva-
lence of CVD risk factors such as hypertension, obesity,
hypertriglyceridemia, and lifestyle differences. Another
possible explanation for the inconsistency might be due
to the fact that FPG differentially correlated with HbA1c
among different ethnic populations as several recentplasma glucose only, HbA1c only, and by both criteria
f HbA1c-based diagnosis of
MetS
MetS by both FPG and HbA1c
(overlap*)
353 (39.5) 361 (40.4)
519 (46.5) 407 (36.5)
176 (46.7) 113 (30.0)
475 (42.7) 423 (38.0)
221 (42.6) 232 (44.7)
409 (45.0) 310 (34.1)
395 (43.8) 359 (39.8)
68 (34.3) 99 (50.0)
119 (50.6) 72 (30.6)
753 (42.5) 696 (39.3)
101 (50.5) 53 (26.5)
346 (43.1) 307 (38.2)
425 (42.3) 408 (40.6)
287 (42.9) 236 (35.3)
585 (43.7) 532 (39.7)
392 (42.6) 304 (33.0)
480 (44.1) 464 (42.6)
471 (45.4) 396 (38.2)
232 (40.5) 220 (38.4)
169 (42.6) 152 (38.3)
ulated as the number of MetS by both FPG and HbA1c divided by the number
ood pressure.
Table 3 Characteristics of participants stratified by diagnosis of metabolic syndrome (MetS) according to fasting
plasma glucose or HbA1c or both
No MetS FPG-based diagnosis of MetS HbA1c-based diagnosis of MetS MetS by both FPG
and HbA1c
Female (%) 51.5 51.4 59.5 53.0
Age (years)§ 48.2 ± 15.0*† ‡ 53.6 ± 12.2* 56.1 ± 13.2* 58.2 ± 12.1
Body mass index (kg/m2)§ 22.6 ± 3.1*† ‡ 25.3 ± 3.1* 25.4 ± 3.1* 26.1 ± 3.4
Waist circumference (cm)§ 79.8 ± 9.4*† ‡ 89.1 ± 8.0* 89.3 ± 8.4* 91.5 ± 8.7
Systolic blood pressure (mmHg) 120.0 (110.0-128.7)*† ‡ 130.0 (120.0-142.3)* 131.0 (120.0-144.7)* 136.0 (123.3-149.3)
Diastolic blood pressure (mmHg) 79.3 (70.7-83.3)*† ‡ 85.0 (80.0-90.7) 86.0 (80.0-91.0) 86.7 (80.0-91.8)
Fasting plasma glucose (mmol/l) 4.9 (4.6-5.3)*† ‡ 5.9 (5.7-6.3) 5.0 (4.7-5.3)*† 6.4 (5.9-7.5)
HbA1c (%) 5.4 (5.1-5.6)*‡ 5.4 (5.2-5.5)* 5.9 (5.8-6.1)*† 6.2 (5.9-6.8)
Total cholesterol (mmol/l) 4.7 (4.1-5.3)*‡ 4.9 (4.3-5.7)* 5.0 (4.5-5.7)* 5.3 (4.7-6.0)
Triglycerides (mmol/l) 1.1 (0.8-1.5)*† ‡ 2.0 (1.3-2.7) 1.8 (1.2-2.5) 1.9 (1.3-2.8)
LDL cholesterol (mmol/l) 2.8 (2.3-3.4)*† ‡ 3.0 (2.3-3.5)* 3.1 (2.5-3.8)† 3.3 (2.6-3.9)
HDL cholesterol (mmol/l) 1.4 (1.2-1.7)*† ‡ 1.2 (1.0-1.5) 1.2 (1.1-1.5) 1.2 (1.0-1.4)
Uric acid (mmol/l) 286.0 (233.0-349.0)*† ‡ 336.5 (281.5-411.0) 318.0 (256.0-377.0))*† 328.0 (267.0-393.0)
HOMA2-IR 1.3 (0.9-1.8)*† ‡ 1.9 (1.4-2.9)* 1.6 (1.2-2.2)* 2.2 (1.5-3.5)
Hemoglobin (g/dl) 141.0 (130.0-153.0)*† 145.0 (133.0-157.0) 142.0 (131.0-154.0)* 146.0 (135.0-159.0)
Albumin (g/dl) 47.3 (45.3-49.5) 47.5 (45.5-49.7) 47.3 (45.3-49.3) 47.8 (45.7-49.8)
Alanine aminotransferase (UI/L) 17.0 (13.0-25.0)*† ‡ 21.0 (14.0-31.5)* 21.0 (15.0-29.0)* 23.0 (17.0-32.5)
Estimated glomerular filtration rate
(ml/min per 1.73 m2)
76.7 (68.2-86.6)*† 73.7 (65.0-82.8) 74.4 (66.2-83.3) 72.8 (63.4-82.2)
C-reactive protein (mg/l) 1.0 (0.0-2.0)*‡ 1.0 (1.0-3.0)* 2.0 (1.0-3.0) 2.0 (1.0-4.0)
Serum magnesium 0.9 (0.9-1.0)*‡ 0.9 (0.9-1.0)* 1.0 (0.9-1.0)† 1.0 (0.9-1.0)
Transferrin (ng/ml) 2.8 (2.5-3.1)*‡ 2.8 (2.5-3.1)* 2.9 (2.6-3.3)† 3.0 (2.6-3.3)
Soluble Transferrin receptor (ng/ml) 1.3 (1.1-1.6) 1.3 (1.1-1.7) 1.3 (1.0-1.6) 1.3 (1.1-1.6)
White blood cell count (×109/ml) 6.0 (5.0-7.1)*‡ 6.1 (5.1-7.3)* 6.2 (5.3-7.5)* 6.5 (5.6-7.7)
Data are medians (25th to 75th percentiles) or percent, except variables denoted by §, which are means ± SD.
*P < 0.001 compared with individuals with MetS according to both FPG and HbA1c.
†P < 0.001 compared with individuals with MetS according to FPG only.
‡P < 0.001 compared with individuals with MetS according to HbA1c only.
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FPG in various populations and have found significant
discordance [11,20]. HbA1c correlates better with insu-
lin resistance than FPG [21]. To date, differences in the
relation of FPG and HbA1c to insulin resistance and in-
sulin secretion have been little described in Chinese
population. One study conducted in Japanese popula-
tion indicated that high normal HbA1c levels (5.4–
5.8%) were associated with impaired insulin secretion
without marked insulin resistance and elevated HbA1c
levels (≥5.9%) were associated with substantial impair-
ment in insulin secretion, insulin sensitivity and β-cell
dysfunction [21], while one Chinese population based
study suggested that increased FPG is predominately in-
duced by the decline in insulin sensitivity and insulin se-
cretion, with the insulin secretion more pronounced
[22]. Taken together, it is possible that how well HbA1cperforms as compared with FPG for the identification of
MetS will depend on the target population.
The limited overlap between HbA1c- and FPG-based
diagnosis of MetS highlights different facets of glucose me-
tabolism and multifactorial pathophysiologic mechanisms
for glucose dysfunction [23-25]. In contrast to daily pre-
prandial glucose snapshot offered by FPG, HbA1c captures
chronic hyperglycemia, including postprandial glucose
spikes. Increased FPG is predominately induced by
liver insulin resistance and a defect in the early phase
of insulin secretion [23,25], whereas increased HbA1c is
dominated by a combination of hepatic insulin resist-
ance, muscle insulin resistance and impaired insulin secre-
tion [24,25]. Although the explanations for the significantly
higher proportion of HbA1c-based diagnosis of MetS in
women compared with men observed in the present study
remain to be elucidated, it is probably related to gender
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ence in gender-specific glucose absorption pattern is a con-
sequence of the relatively higher dose of glucose given to
women compared with men when seen in relation to their
body size [27,28]. Several studies have shown that men in
general have a higher prevalence of isolated impaired fast-
ing glucose than do women [27,28]. In contrast, women
often exhibit a higher prevalence of isolated impaired glu-
cose tolerance [27,28]. Monnier et al. found that the rela-
tive contribution of postprandial hyperglycemia accounted
for ~70% of overall glycemic exposure in patients with
HbA1c <7.3%, while the relative contribution of FPG in-
creased gradually with increasing levels of HbA1c [29]. In
the present study, we noted that only 8 (0.9%) individuals
had HbA1c ≥7.3% among the 872 individuals with HbA1c-
based definition of MetS (data not shown), indicating a
greater contribution of postprandial versus FPG to HbA1c
levels. Hence, the HbA1c-based definition of MetS re-
flects more of the postprandial glucose-based diagnosis
of MetS. Taken together, it is possible that women carry
a higher prevalence of HbA1c-based diagnosis of MetS
than do men. A greater contribution of postprandial
versus FPG to HbA1c levels may also in part explain the
limited overlap between FPG and HbA1c-based defin-
ition of MetS.
Subgroup differences were noted in the present study,
with a slightly higher magnitude of overlap between FPG
and HbA1c-based definition of MetS among persons
with older age, elevated BMI, WC, and BP. One possible
explanation for this relatively low discrepancy in older
age might be the fact that the prevalence of MetS was
more frequent among older persons [5,30]. The rela-
tively low discrepancy in worsening BMI, WC, and BP
status might be attributed to the fact that obesity, en-
larged waist, and hypertension accompany the insulin-
resistant state that underlies the MetS.
In this study, individuals with FPG-based identification
of MetS had different characteristics compared with indi-
viduals with HbA1c-based identification of MetS. The dif-
ferent characteristics might affect progression to CVD
mortality and morbidity within each case of discordantly
diagnosed MetS. Most components of the MetS are re-
quired to be conducted in the fasting state, although an
overnight fast is not required for HbA1c measurement, it
is possible that clinicians can have access to both FPG and
HbA1c in most of their patients. In this context, and based
on our data, the MetS rate may increase by approximately
70% if both FPG and HbA1c are measured. Although
there is controversy whether the diagnosis of MetS con-
veys additional cardiovascular risk in subjects with dia-
betes [12-14], a recent meta-analysis evidenced that in the
absence of type 2 diabetes mellitus, the MetS was associ-
ated with an increased risk of cardiovascular mortality
(RR: 1.75; 95% CI: 1.19 to 2.58) [3]. Our present studyshowed that in participants without diabetes, even more
limited overlap between HbA1c- and FPG-based diagnosis
of MetS was observed. The identification of MetS is of
clinical importance because appropriate interventions can
clearly prevent or delay the CVD mortality and morbidity,
especially in subjects without diabetes. Although evidence
suggested that there was no linear relationship between
FPG and CVD mortality and morbidity [31], the risk
for diabetes and CVD mortality and morbidity increased
gradually with rising FPG and HbA1c [32,33]. Two pro-
spective studies demonstrated that the combined use of
FPG and HbA1c were more predictive of the risk of future
diabetes [34,35]. Our finding that individuals with Mets
based on both FPG and HbA1c were older, more obese,
hypertensive, dyslipidemic, and insulin resistant and had
higher CRP compared with individuals with Mets based
on FPG alone or HbA1c alone further supported the no-
tion. Therefore, individuals with Mets based on both
measure might allow for assessment of a substantially in-
creased risk of CVD mortality and morbidity. We believe
that introduction of HbA1c into FPG is appropriate for
detection of MetS, and will contribute to cover a larger
number of people being submitted to aggressive drug regi-
mens to prevent future risk for diabetes and CVD mortal-
ity and morbidity. Further large-scale longitudinal studies
are, however, required to address this issue.
Our study has several strengths including a well-
established cohort of nationally representative sample of
the Chinese adult population, a vigorous quality assur-
ance program, the same strict methodology used to en-
sure the quality of the data collection over the entire
study period, and the centralization of laboratory mea-
surements. We also benefited from the CHNS 2009′s
availability of broad range of demographic, clinical, and
biomarker data collected by trained staff. Nevertheless,
the current study was subjected to several limitations.
First, we got availability of only single measures of all bio-
chemical variables, a common limitation to most large epi-
demiologic studies. Second, since the current study is a
cross-sectional design, we cannot explore whether diagno-
sis of MetS based on different measures have the same
predictive capacity in the risk of future diabetes and CVD
mortality and morbidity. Third, estimates across sub-
groups should also be interpreted with caution because of
limited sample size.Conclusion
In summary, limited overlap and poor agreement are
demonstrated between the FPG- and HbA1c-based diag-
nosis of MetS. Screening MetS through introduction of
HbA1c in addition to FPG could contribute to identifi-
cation of more people with MetS who would otherwise
have been missed.
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